{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-220060","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.684431+00:00","generated_at":"2026-06-24T00:17:33.336619+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Forte Biosciences files prospectus supplement for additional $2.7M ATM offering","bullets":["Filed new prospectus supplement for sale of up to $2.7M of common stock via existing ATM agreement with Ladenburg Thalmann.","Aggregate offering under the ATM agreement remains capped at $25M; previously $7M was registered.","Proceeds to be used for general corporate purposes, including funding existing and potential new clinical programs.","Shares issued under previously effective S-3 registration statement filed May 28, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-220060","json":"https://secwatch.observer/filing/0001193125-22-220060.json","markdown":"https://secwatch.observer/filing/0001193125-22-220060.md","text":"https://secwatch.observer/filing/0001193125-22-220060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522220060/0001193125-22-220060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522220060/d365470d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:17:33.336619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}